Glycanostics® has developed an early-stage, highly accurate and unique cancer diagnostic test that analyses changes in glycan structures in glycoprotein biomarkers from blood serum. Giasay® Prostate cancer test is being launched in Europe in Q2 2023, to be followed by Giasay®breast cancer test at the end of 2023. Our PCT patent also covers lung cancer, pancreatic cancer, ovarian, testicular, bladder, stomach, liver, colorectal and thyroid cancer.
Giasay® test has the following unique features:
- It is minimally invasive (it analyses glycans from blood serum),
- It detects early stage of the disease with high accuracy,
- It is fast and easy to work with,
- Affordable,
- It reduces the number of false-positive results significantly,
- It is compatible with equipment already used by laboratories world-wide (ELISA),
- It also provides solutions for large-scale screening,
- It is organ specific, and
- Suitable for disease monitoring.
Giasay® test has the following unique features:
- It is minimally invasive (it analyses glycans from blood serum),
- It detects early stage of the disease with high accuracy,
- It is fast and easy to work with,
- Affordable,
- It reduces the number of false-positive results significantly,
- It is compatible with equipment already used by laboratories world-wide (ELISA),
- It also provides solutions for large-scale screening,
- It is organ specific, and
- Suitable for disease monitoring.
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
